| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Columbamine chloride targets various biological pathways through its protoberberine alkaloid structure. As an isoquinoline alkaloid, it may interact with enzymes, receptors, and ion channels. Its antimicrobial activity suggests interactions with microbial cell components. Its anti-inflammatory activity may involve modulation of inflammatory cytokine production. Its anticancer properties suggest interactions with pathways regulating cell proliferation and apoptosis. Further research is needed to identify its specific molecular targets and mechanisms of action.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Columbamine chloride exhibits antimicrobial, anti-inflammatory, and anticancer activities. Its antimicrobial activity has been assessed against various bacterial and fungal strains. Its anti-inflammatory activity has been evaluated in cell-based assays measuring cytokine production. Its anticancer activity has been demonstrated in various cancer cell lines. These in vitro findings support its potential applications in natural product research and drug discovery.
|
| ln Vivo |
In vivo studies of Columbamine chloride are limited as the compound is primarily used as a research chemical. As a naturally occurring alkaloid found in medicinal plants, it may contribute to the pharmacological effects of plant extracts. Its antimicrobial, anti-inflammatory, and anticancer activities suggest potential for in vivo evaluation in relevant disease models. However, comprehensive in vivo pharmacological studies specifically targeting Columbamine chloride are not well documented in the available literature. The compound is intended for research use only.
|
| Enzyme Assay |
In vitro enzyme assays for Columbamine chloride typically involve testing its antimicrobial, anti-inflammatory, and anticancer activities. Antimicrobial activity is assessed using standard disc diffusion or broth microdilution methods. Anti-inflammatory activity is assessed by measuring inhibition of COX, LOX, or other inflammatory enzymes. Anticancer activity is assessed using cell viability assays. All assays are performed with appropriate controls and standardized protocols.
|
| Cell Assay |
In vitro cell-based assays for Columbamine chloride involve culturing cancer cell lines to evaluate its anticancer activity. Cells are treated with varying concentrations of the compound and cell viability is assessed using MTT or similar colorimetric assays. Apoptosis is quantified using flow cytometry with Annexin V/PI staining. For anti-inflammatory studies, immune cells are treated with the compound and stimulated with inflammatory stimuli; cytokine production is measured by ELISA. All experiments are performed in triplicate with appropriate controls.
|
| Animal Protocol |
In vivo animal experiments for Columbamine chloride would be conducted to evaluate its antimicrobial, anti-inflammatory, and anticancer activities. For antimicrobial studies, infected animals would be treated and pathogen load assessed. For anti-inflammatory studies, animals with induced inflammation would be treated and inflammatory markers measured. For anticancer studies, tumor-bearing animals would be treated and tumor growth monitored. Parameters assessed would include body weight, organ weights, and histopathology. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Columbamine chloride reflect its nature as a protoberberine alkaloid. It has a molecular formula of C20H20ClNO4. As a quaternary ammonium alkaloid, it has limited oral bioavailability. The compound is expected to be metabolized through standard xenobiotic pathways in the liver. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Columbamine chloride has been evaluated in the context of its use as a research chemical. As a naturally occurring alkaloid, it may have biological effects that should be carefully evaluated. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile.
|
| References | |
| Additional Infomation |
Columbamine chloride (CAS# 1916-10-5) is also known as Dehydroisocorypalmine chloride. It is a protoberberine alkaloid with the molecular formula C20H20ClNO4. It is a naturally occurring isoquinoline alkaloid found in various plant species including Coptis chinensis. Columbamine chloride exhibits various biological activities including antimicrobial, anti-inflammatory, and anticancer properties. The compound is used in research applications for studying alkaloid chemistry and natural product pharmacology. It is intended for research use only.
|
| Molecular Formula |
C20H20CLNO4
|
|---|---|
| Molecular Weight |
373.83
|
| Exact Mass |
373.108
|
| CAS # |
1916-10-5
|
| Related CAS # |
Columbamine; 3621-36-1
|
| PubChem CID |
15840198
|
| Appearance |
Light yellow to yellow solid
|
| Vapour Pressure |
3.37E-17mmHg at 25°C
|
| LogP |
0.085
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
461
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Cl-].O(C([H])([H])[H])C1=C(C([H])=C([H])C2C1=C([H])[N+]1=C(C=2[H])C2=C([H])C(=C(C([H])=C2C([H])([H])C1([H])[H])OC([H])([H])[H])O[H])OC([H])([H])[H]
|
| InChi Key |
KDUDGYVKQSKHQG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H19NO4.ClH/c1-23-18-5-4-12-8-16-14-10-17(22)19(24-2)9-13(14)6-7-21(16)11-15(12)20(18)25-3;/h4-5,8-11H,6-7H2,1-3H3;1H
|
| Chemical Name |
3,9,10-trimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-2-ol;chloride
|
| Synonyms |
Dehydroisocorypalmine chloride; Columbamine chloride; Columbamin chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 5 mg/mL (13.38 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6750 mL | 13.3751 mL | 26.7501 mL | |
| 5 mM | 0.5350 mL | 2.6750 mL | 5.3500 mL | |
| 10 mM | 0.2675 mL | 1.3375 mL | 2.6750 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
